Strengthening the clinical leadership as the Company progresses to the clinic with its BRD9 Targeted Glue, AMX-883, in acute myeloid leukemiaAmphista continues to advance its SMARCA and TEAD programs ...
Background Alcohol use disorder and treatment-resistant depression (TRD) often co-occur, presenting a major clinical challenge with limited effective treatments. However, ketamine produces rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results